One criterion, applied uniformly: how specifically does the provider disclose the pharmacy that compounds and dispenses your medication? This rewards disclosure, not price. A provider that names the exact 503A and 503B per program discloses more than one that lists a set of possible partners, which in turn discloses more than one that names none.
Scored on disclosure specificity only: (1) names the specific pharmacy per program, (2) discloses 503A/503B type, (3) discloses standards/accreditation. More disclosure ranks higher. This is not a safety ranking of the pharmacies themselves — it measures what the provider tells you.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Pharmacy disclosure | 503A/503B type | Standards cited | Disclosure level | Provenance |
|---|---|---|---|---|---|
| Fifty 410 | Names specific pharmacies: ProRx, BPI | Both named (ProRx 503A, BPI 503B) | LegitScript (stated) | Specific | primary |
| NexLife | Names a set of possible partners (Absolute, Hallandale, Red Rock, Empower, Strive) + unnamed 503B | Both types disclosed; specific filler per order not stated | USP <797>; LegitScript; PCAB "where applicable" | Partial | primary |
| Henry Meds | No pharmacy named publicly | 503A (reported), not named | Not disclosed | Minimal | secondary |
| Mochi Health | No pharmacy named publicly | 503A (reported), not named | Not disclosed | Minimal | secondary |
Ordered by disclosure specificity. Fifty 410 names the exact 503A and 503B per program; NexLife names a set of possible 503A partners and the standards they operate under, but not the specific filler per order; Henry Meds and Mochi name no pharmacy publicly (alphabetical between equals). Naming more does not by itself prove higher quality — it lets you verify.
If you know the specific pharmacy, you can check its state license, look up whether it’s a 503A or FDA-registered 503B, see any FDA warning letters or inspection history, and ask for per-batch testing. If the provider names no pharmacy, none of that is possible — you’re trusting an unnamed filler. Use the pharmacy transparency checklist to ask the right questions.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.